HC Wainwright Analysts Reduce Earnings Estimates for ABEO

Abeona Therapeutics Inc (NASDAQ:ABEO) – Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Abeona Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their prior estimate of ($0.34). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.19.

ABEO has been the subject of several other reports. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $5.04 on Wednesday. The firm has a market capitalization of $219.09 million, a price-to-earnings ratio of -1.87 and a beta of 1.79. The stock has a fifty day moving average of $5.42 and a 200 day moving average of $5.81. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $8.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. purchased a new position in shares of Abeona Therapeutics during the third quarter valued at approximately $151,000. Citigroup Inc. increased its position in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares in the last quarter. Western Standard LLC boosted its holdings in Abeona Therapeutics by 7.0% in the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after acquiring an additional 110,998 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Abeona Therapeutics in the third quarter worth $84,000. Finally, XTX Topco Ltd bought a new position in shares of Abeona Therapeutics during the third quarter valued at $160,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.